ClinicalTrials.gg
CompletedNCT01921647YH4808-108Updated Dec 3, 2013

The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects

A Phase 1 interventional study of YH4808 and Nexium in Healthy, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-03.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The objective of this study is not only to explore pharmacokinetic interaction after single oral administration but also pharmacodynamics interaction after multiple oral administration of YH4808, amoxicillin and clarithromycin each separately versus coadministration of YH4808, amoxicillin and clarithromycin in healthy volunteers

02

Conditions studied

  • Healthy

Keywords

  • safety/tolerability and pharmacokinetics/pharmacodynamics
03

In context

Lead sponsor

Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. healthy male age 20 to 55 over 55kg with Ideal body weight(:18.5\~25)
  2. Subject who has no congenital, chronic disease and disease symptoms in medical examination result
  3. Subject who is judged to be eligible by principal investigator or sub-investigator according to various reasons including their abnormal test results(clinical laboratory test, 12-lead GCG etc)

Exclusion criteria

Exclusion Criteria:

  1. Subject who is hypersensitive to components contained in YH4808 or this drug
  2. Subject who has history or presence of diseases in liver, kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system, blood tumor, cardiovascular, urinary system, and mental disorder
  3. Subject who has history of surgical operation or diseases related to gastrointestinal symptom (e.g. Crohn's disease, ulcer etc except appendectomy or simple for hernia)
  4. Other exclusions apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    YH4808, amoxicillin, clarithromycin

    single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin

    Drug: YH4808 · Drug: Amoxicillin · Drug: clarithromycin

  • Experimental
    YH4808, amoxicillin and clarithromycin

    7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication

    Drug: YH4808 · Drug: Amoxicillin · Drug: clarithromycin

  • Experimental
    YH4808 and amoxicillin

    7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication

    Drug: YH4808 · Drug: Amoxicillin

  • Active comparator
    nexium, amoxicillin and clarithromycin

    BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication

    Drug: Nexium · Drug: Amoxicillin · Drug: clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax, AUClast of YH4808, M3, amoxicillin, clarithromycin, 14-hydroxyclarithromycin

    Time frame: pre dose, 16 times after dosing

Secondary outcomes

  1. Cmax, AUClast of M8, AUCinf, t1/2, Tmax of YH4808, M3, M8, amoxicillin, clarithromycin, 14-hydroxyclarithromycin

    Time frame: pre dose, 16 times after dosing

07

Study locations

1 site
  • Yonsei University Severance Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Park H, Kim CO, Kim M, Lim Y, Lee WY, Yoon S, Park MS. Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Transl Clin Pharmacol. 2020 Sep;28(3):136-146. doi: 10.12793/tcp.2020.28.e16. Epub 2020 Sep 23. PubMed 33062627 ↗
  • Lee WY, Oh E, Cui M, Kim CO, Lim Y, Kim H, Park H, Yoon S, Park MS, Hong T. Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects. Transl Clin Pharmacol. 2020 Mar;28(1):55-65. doi: 10.12793/tcp.2020.28.e5. Epub 2020 Mar 31. PubMed 32274381 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2013
First posted
Aug 13, 2013
Start
Jul 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Dec 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01921647
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Aug 13, 2013
Start date
Jul 2013
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Dec 3, 2013

Study contacts

Min soo Park, Ph.D, M.D.
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: YH4808 · Amoxicillin · Clarithromycin

Start the discussion